Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

Inclusion Criteria: * Male or female (post menopausal and/or surgically sterile) * Aged 18 to 70 years * Treatment naïve subjects with fasting blood glucose levels of 150-220 mg/dL, hematocrit of \>/= 35% and HbA1c levels of \>/= 7% and \</= 10.0% * Subjects on antidiabetic therapy with fasting blood glucose levels of 100-200 mg/dL, hematocrit of \>/= 35%, and HbA1c levels of \>/= 6.5% and \</= 9.0% Exclusion Criteria: * Greater than 3 severe hypoglycemic episodes within six months of screen * Pregnant, breastfeeding, or intends to become pregnant * Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT greater than 1.5 times the upper limit of normal * History of hepatitis B surface antigen, hepatitis C antibody, or HIV * Complications of diabetes (e.g., neuropathy, nephropathy, and retinopathy) * Clinically significant and currently active diseases * Clinically significant abnormalities in medical history, physical examination, or laboratory examination